Deshmukh et al investigated the effect of ranolazine on endothelial-dependent vasodilatation (EDV), serum markers of endothelial dysfunction and inflammation in a randomized, double-blind, placebo-controlled prospective study with a crossover design. Twenty-seven patients (19 males, Mean age (64 +/- 9.0) with stable CAD were randomly assigned to either 1000 mg twice daily of ranolazine or to matching placebo, for 6 weeks and then crossed over for an additional 6 weeks. EDV was assessed using PAT reactive hyperemia Index (RHI) at baseline, 6 and 12 weeks. After 6 weeks, treatment with ranolazine significantly increased RHI as compared with baseline (1.85± 0.42 vs. 2.08± 0.57, P = 0.037). RHI did not change in the placebo group (1.69± 0.35 vs. 1.78±0.41, P =0.29). |
|
 |
